Affinity DataKi: 104nMAssay Description:Binding affinity to 5-HT2B receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: 195nMAssay Description:Binding affinity to 5-HT7 receptor (unknown origin)More data for this Ligand-Target Pair
TargetSigma non-opioid intracellular receptor 1(Homo sapiens (Human))
University Of Missouri
Curated by ChEMBL
University Of Missouri
Curated by ChEMBL
Affinity DataKi: 220nMAssay Description:Binding affinity to sigma1 receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: 257nMAssay Description:Binding affinity to 5-HT2A receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: 286nMAssay Description:Binding affinity to adrenergic alpha 1A receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: 293nMAssay Description:Binding affinity to adrenergic alpha 1D receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: 407nMAssay Description:Binding affinity to adrenergic alpha 2A receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: 446nMAssay Description:Binding affinity to adrenergic alpha 2C receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:Binding affinity to cannabinoid CB1 receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:Binding affinity to cannabinoid CB2 receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:Binding affinity to adenosine A1 receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:Binding affinity to SST2 receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:Binding affinity to SST4 receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:Binding affinity to adenosine A2A receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:Binding affinity to adenosine A3 receptor (unknown origin)More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 20.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 20.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 20.8nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 20.8nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 23.0nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 23nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 32.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 32.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 34.1nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 34.1nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 35.7nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 35.7nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 36.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 36.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 37.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 37.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 39.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 47.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 47.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48.0nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 50.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 50.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 51.3nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 52.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 52.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 53.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 60nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 60nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 60.3nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 60.3nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair